23 results about "Osmotic pump" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to a rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition and a preparation method thereof, and the rapamycin multiphase release or osmotic pump type weekly-effect oral controlled-release composition comprises a quick release layer, a slow release layer and an osmotic pump structural design. According to the application, staged or constant-rate release of rapamycin within 168 hours is realized through a multi-phase release technology or an osmotic pump technology, and the problems that an existing preparation is large in blood concentration fluctuation, high in administration frequency and low in bioavailability are solved. The composition is suitable for treating hypertrophic cardiomyopathy of cats, significantly improves cardiac functions and reduces side effects and risks, is administered once a week, and is convenient to use. The invention further provides a storage method, and the product stability is ensured. The technical scheme has remarkable clinical advantages and application prospects.

A water treatment plant or system for the production of permeate includes a reverse osmosis stage and a permeate stage. The reverse osmosis stage can include a piping system having a supply line for process input water, a reverse osmosis pump, and a reverse osmosis tank. The reverse osmosis tank has an inlet for process input water coming from the reverse osmosis pump, a membrane, and an outlet for permeate. The permeate stage, which can have a line system forming a circuit, can include a permeate tank, a permeate pump, and a tapping point for connecting at least one consumer or user of permeate. The reverse osmosis stage and the permeate stage can be connected to one another via a connecting line in such a way that the reverse osmosis stage feeds the permeate stage with permeate. The circuit of the permeate stage can include a sterile filter.

An electro-osmotic pump according to an embodiment of the present disclosure includes: a membrane that allows fluid movement; and a first electrode and a second electrode respectively provided on both sides of the membrane. The first electrode and the second electrode are formed of an impermeable substrate material and an electrode material coated thereon and have at least one fluid pathway. The impermeable substrate material is a plate-shaped substrate including at least one of a conducting material, a semiconducing material and a non-conducting material.

Main requirement: Water treatment plant for the production of permeate, especially for dialysis therapy, comprising • a reverse osmosis stage (137) with a piping system comprising a supply line (131) for process inlet water (100), a reverse osmosis pump (103) and a reverse osmosis tank (130), wherein the reverse osmosis tank (130) has an inlet (143) for the process inlet water (100) coming from the reverse osmosis pump (103), a membrane (104) and an outlet (144) for permeate (108), • a permeate stage (139) with a circulating piping system comprising a permeate tank (112), a permeate pump (114) and a take-off point (134) for connecting at least one consumer or user of permeate (108), wherein the reverse osmosis stage (137) and the permeate stage (139) are connected to each other via a connecting line (138) such that the reverse osmosis stage (137) feeds the permeate stage (139) with permeate (108), and wherein the circuit of the permeate stage (138) comprises a sterile filter (116).

The invention provides a nicotine osmotic pump tablet and a preparation method thereof, the nicotine osmotic pump tablet is suitable for the oral cavity, the nicotine osmotic pump tablet comprises a tablet core, the tablet core comprises a drug-containing layer and a boosting layer, the drug-containing layer contains nicotine, and the ratio of the viscosity of the drug-containing layer to the viscosity of the boosting layer is 1: 1.5-1: 2; the tablet core is coated with the semi-permeable membrane; and the release hole can release nicotine after the semipermeable membrane permeates into the liquid. By adopting the nicotine osmotic pump tablet, nicotine is released at an approximately constant rate, the problems that oral mucosa and even stomach are stimulated to cause nausea and the like due to too fast release of nicotine are avoided, and meanwhile, sticky feeling or foreign body sensation is avoided during oral administration.

The application provides a tivozanib hydrochloride osmotic pump controlled-release tablet, which is characterized in that the tablet comprises a tablet core, and the tablet core comprises 100 parts of tivozanib hydrochloride, 30-60 parts of a retarder, 40-80 parts of a disintegrant and / or an osmotic pressure promoter, 40-90 parts of a cosolvent and 8-15 parts of a pore-forming agent in terms of weight fraction. The tivozanib hydrochloride osmotic pump controlled-release tablet can realize zero-order release and has a 24-hour cumulative release degree of more than 96%, so that the bioavailability of tivozanib in vivo is improved, and the frequency or dosage of oral solid preparations of tivozanib is reduced.

The invention relates to a detachable multi-organ chip co-culture device, and relates to the technical field of biological tissue engineering. Comprising an upper-layer fluid channel layer chip, a lower-layer micro-pit cell culture layer chip and an osmotic pump, the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are respectively divided into five independent functional units, and the structures of the independent functional units are mutually independent; each independent functional unit of the upper fluid channel layer chip comprises a fluid channel structure; each independent functional unit of the lower-layer micro-pit cell culture layer chip comprises a micro-pit array structure and a micro-cavity, and the micro-pit array structure is arranged at the bottom of the micro-cavity; the upper-layer fluid channel layer chip and the lower-layer micro-pit cell culture layer chip are detachably combined and connected through a tenon-and-mortise structure; the osmotic pump is connected to the outlet end of the culture device and is used for constructing a dynamic perfusion culture environment. According to the invention, high-throughput culture of multiple organs can be realized, and the cell viability and proliferation state are good under a dynamic perfusion condition.

An osmotic pump tablet, its preparation method and use. The osmotic pump tablet comprises a tablet core and a coating film wrapping the tablet core, the coating film has a drug release hole, the tablet core comprises a drug-containing layer, the drug-containing layer comprises a drug active ingredient, a hydrophilic polymer and a surfactant, the hydrophilic polymer comprises hydroxypropyl cellulose and the surfactant comprises poloxamer; or the drug-containing layer comprises a drug active ingredient and a hydrophilic polymer but does not contain a surfactant; the hydrophilic polymer comprises povidone K29 / 32; or the osmotic pump tablet comprises a drug-containing immediate-release outer coating, the drug-containing immediate-release outer coating comprises a drug active ingredient and a pharmaceutical excipient, and the pharmaceutical excipient is a binder.

The invention relates to a nicotine osmotic pump tablet for oral cavity and a preparation method thereof. The nicotine osmotic pump tablet for the oral cavity comprises a tablet core, the tablet core comprises a medicine layer and a boosting layer, the medicine layer comprises nicotine and a hydrophilic polymer, and the boosting layer comprises an osmotic pressure accelerant, an insoluble expanding agent and a hydrophilic polymer; the semipermeable membrane covers the tablet core, the weight of the semipermeable membrane accounts for less than 10% of the weight of the tablet core, the semipermeable membrane comprises a base material and a pore-foaming agent, and the weight of the pore-foaming agent accounts for 10%-20% of the weight of the semipermeable membrane; and the release hole can release the nicotine after the semipermeable membrane permeates into the liquid. The nicotine osmotic pump tablet for the oral cavity can adapt to the oral cavity environment, meets the core requirement of applying nicotine to the oral cavity, has no rupture condition in the nicotine dissolution process, is better in mechanical property, and can be accurately, rapidly and completely released in the oral cavity environment in a short time in a staged manner.

The invention discloses a preparation method of a theophylline controlled-release tablet and the theophylline controlled-release tablet. The preparation method comprises the following steps: S1, dry granulation of a medicine layer: preparing medicine layer particles from theophylline, a slow-release hydrophilic polymer material, a moisture absorbent, a flow aid and a lubricant; s2, performing dry granulation on the boosting layer: preparing boosting layer particles from a coloring material, an expansive high polymer material, a moisture absorbent, a flow aid and a lubricant; s3, tabletting of double-layer tablets: adding the medicine layer particles and the boosting layer particles into a double-layer tablet press for tabletting; s4, semi-permeable membrane coating: adding the theophylline double-layer tablet chip and a semi-permeable membrane coating solution into a coating machine; and S5, laser drilling: drilling holes in the theophylline double-layer semi-permeable membrane coating tablets through a laser drilling machine. The osmotic pump controlled release technology is utilized to control the constant-speed release of the medicine, the medicine effect is more lasting, the plasma concentration is stable, the adverse reaction of the medicine is effectively reduced, the medicine taking frequency is reduced, the medicine taking compliance of a patient is improved, and the clinical treatment effect of the medicine is improved.

Main claim: Water treatment plant for the production of permeate, in particular for dialysis therapy, comprising: • a reverse osmosis stage (137) with a piping system comprising a supply line (131) for process inlet water (100), a reverse osmosis pump (103) and a reverse osmosis tank (130), wherein the reverse osmosis tank (130) has an inlet (143) for the process inlet water (100) coming from the reverse osmosis pump (103), a membrane (104) and an outlet (144) for permeate (108), • a permeate stage (139) with a circulating piping system comprising a permeate tank (112), a permeate pump (114) and a discharge point (134) for connecting at least one consumer or user of permeate (108), wherein the reverse osmosis stage (137) and the permeate stage (139) are connected to each other via a connecting line (138) such that the reverse osmosis stage (137) feeds the permeate stage (139) with permeate (108),and wherein the permeate stage circuit (138) includes a sterile filter (116).

The present application relates to a kind of poorly soluble drug osmotic pump controlled-release tablets and its preparation method, the osmotic pump controlled-release tablets include tablet core, semi-permeable membrane coating and release hole, the tablet core includes solid dispersion of poorly soluble drug and penetration agent, the solid dispersion of poorly soluble drug includes poorly soluble drug and carrier, the poorly soluble drug is selected from nicardipine, nifedipine, felodipine and their pharmaceutically acceptable salt, the carrier is selected from organic acid substance.Compared with prior art, the poorly soluble drug osmotic pump controlled-release tablets of the present application greatly improves the drug solubility, without using a large amount of penetration agent or other excipients in tablet core, drug loading is increased, and tablet core will not be too large;In vivo release greatly improves;Preparation process is simple, equipment requirement and cost are low, and easy to industrialization.

The present application provides a kind of felodipine osmotic pump controlled-release tablets and preparation method thereof, the osmotic pump controlled-release tablet is composed of osmotic pump controlled-release tablet core and water-insoluble coating layer (single side laser punching), the weight percentage of the felodipine osmotic pump controlled-release tablet contains immediate-release coating layer, controlled-release coating layer, propelling coating layer, water-insoluble coating layer is (5~20) :(5~30) :(10~50) :(5~30).The present application also provides a kind of preparation method of felodipine osmotic pump controlled-release tablet and its application in treating hypertension.The formulation of the felodipine osmotic pump controlled-release tablet of the present application is reasonable, and production process is simple and easy to control;By replacing traditional controlled-release tablet polyethylene oxide with different povidone, the controllability of felodipine osmotic pump controlled-release tablet preparation is significantly improved, and the difficulty of cleaning in production is reduced.

The invention relates to a water treatment device for producing a permeate, in particular for dialysis treatments, comprising: a reverse osmosis stage having a line system comprising an input line for process input water, a reverse osmosis pump and a reverse osmosis container, wherein the reverse osmosis vessel has an inlet for process input water from a reverse osmosis pump, a membrane and an outlet for permeate; the invention relates to a reverse osmosis system comprising a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage, a reverse osmosis stage and a reverse osmosis stage, the reverse osmosis stage supplies permeate to the permeate stage, and wherein the loop of the permeate stage comprises a sterile filter.

The utility model relates to the technical field of water treatment, in particular to a highly integrated pure water treatment device which comprises an integrated frame, a precision filter, a water inlet header pipe, a first-stage reverse osmosis pump, a first-stage RO membrane, a second-stage reverse osmosis pump and a second-stage RO membrane are arranged in the integrated frame, an inlet of the precision filter is communicated with the water inlet header pipe, and an outlet of the precision filter is communicated with the water inlet header pipe. An outlet of the precision filter is connected with a first-stage reverse osmosis pump, an outlet of the first-stage reverse osmosis pump is connected with a first-stage RO membrane, a concentrated water outlet of the first-stage RO membrane is communicated to a trench through a pipeline, a pure water outlet of the first-stage RO membrane is connected with a second-stage reverse osmosis pump, and an outlet of the second-stage reverse osmosis pump is communicated with a second-stage RO membrane; a pure water outlet of the second-stage RO membrane is connected between the first-stage RO pump and the water inlet header pipe through a pipeline, a pure water outlet of the second-stage RO membrane is connected to the pure water tank through a water pipe, and a control system is arranged in the integrated frame, so that the effects that the occupied space of the pure water treatment device is smaller, and the pure water preparation rate is higher are achieved.

The invention discloses a citric acid tofacitinib osmotic pump sustained-release tablet, which comprises a citric acid tofacitinib tablet core and a sustained-release coating layer coated on the surface of the citric acid tofacitinib tablet core, the citric acid tofacitinib tablet core contains a waxy framework material, and the sustained-release coating layer contains a sustained-release membrane material and a pore-foaming agent; the slow-release membrane material is composed of eudragit RL and eudragit RS; the pore-foaming agent is a water-soluble pore-foaming agent. The invention also discloses a preparation method of the tofacitinib citrate osmotic pump sustained release tablet, which comprises the following steps: uniformly mixing the components of the tablet core, and tabletting to obtain the tablet core; coating the tablet core, preserving heat and curing to obtain the tofacitinib citrate osmotic pump sustained release tablet. According to the invention, the corrosion controlled release of the waxy framework material and the controlled release coating layer are hierarchically coupled, so that the drug release stability is obviously improved, the tolerance to the change of the gastrointestinal tract physiological environment is stronger, and the dissolution of the drug is not reduced after long-term storage.

The invention discloses an oral abutment with a drug sustained release function, and relates to the technical field of medical implantation. In order to solve the problem of poor treatment effect caused by insufficient drug concentration in the prior art, the invention designs the oral cavity abutment with the drug sustained-release function, and the oral cavity abutment is mainly structurally characterized by having three drug release modes which are mutually matched and linked; comprising a continuous release mode structure, an inflammation release mode structure and a stress release mode structure, in a daily state, a proper amount of medicine is continuously released through an osmotic pump, and the basic treatment concentration is maintained; after the mucosa around the implant is inflamed, the temperature rise of the inflammation part is detected, and the medicine release amount is increased through an inflammation release mode structure so as to strengthen the treatment effect; when a patient presses and occludes, the drug release amount is further supplemented through the stress release mode structure. According to the invention, the treatment effect on the mucositis around the implant is obviously improved, and the repair and regeneration of tissues around the implant are promoted.

The invention relates to the technical field of sustained-release preparations, and particularly discloses a gentiopicroside sustained-release preparation and a preparation process thereof, and the gentiopicroside sustained-release preparation is technically characterized in that the sustained-release preparation is a microporous osmotic pump tablet or a skeleton sustained-release tablet; the microporous osmotic pump tablet comprises a tablet core and a coating, wherein the tablet core is composed of gentiopicroside and auxiliary materials; the auxiliary materials comprise ethyl cellulose, microcrystalline cellulose, magnesium stearate and 60% ethanol; the coating is composed of ethyl cellulose, PEG 6000, triethyl citrate and ethyl alcohol, and the weight of the coating is increased by 4%-10%. According to the scheme, the problems of short half-life period and short in-vivo time of the gentiopicroside are solved, the gentiopicroside microporous osmotic pump tablet (GPS-MPOP) and the skeleton sustained release tablet (GPS-MRT) are prepared respectively, the in-vitro drug release behavior, the drug release mechanism and in-vivo pharmacokinetics of the gentiopicroside microporous osmotic pump tablet and the skeleton sustained release tablet are studied, and the scheme proves that the release characteristic of the gentiopicroside is remarkably improved, so that the gentiopicroside can be applied to the field of pharmaceutical preparations. And new technical support and theoretical basis are provided for clinical application.

Disclosed in the present invention are a topiroxostat osmotic pump tablet and a preparation method therefor. The topiroxostat osmotic pump tablet comprises: a tablet core consisting of a drug layer and a push layer; a semipermeable membrane coating outside the tablet core; a single drug-release orifice on the controlled-release tablet surface on the side of the drug layer; and an isolation film coating. Compared with topiroxostat tablets currently on the market, the topiroxostat osmotic pump controlled-release tablet prepared in the present invention achieves sustained and stable constant-rate drug release. The drug in a drug-release layer is not released immediately after a patient takes the drug; within the ten or more hours thereafter, the tablet can release the drug rhythmically under the action of the push layer, maintaining a steady-state plasma concentration, delaying the time at which the peak is reached, and prolonging the half-life of the drug, thereby improving bioavailability and achieving a sustained release effect of 12 h or more. Because a dual-layer osmotic pump controlled-release technology is used, the drug has stronger controllability, a more complete release, and higher bioavailability in comparison with single-layer tablets.

The invention relates to an osmotic pump type controlled release tablet preparation as well as a preparation method and application thereof. The osmotic pump type controlled release tablet preparation is a double-layer controlled release tablet and comprises a double-layer tablet core and a semi-permeable membrane coating, the double-layer tablet core comprises a medicine carrying layer and a pushing layer, and at least one channel hole is formed in the side, close to the medicine carrying layer, of the semi-permeable membrane coating and connected with the medicine carrying layer and the outside, so that medicine can be released. The osmotic pump type controlled release tablet disclosed by the invention has a curative effect consistent with that of a commercially available product, is more suitable for being produced by domestic pharmaceutical production enterprises, has lower production cost, and is small in batch-to-batch difference in dissolution speed and safe in medication.

The invention relates to the technical field of pharmaceutical preparations, in particular to a cilnidipine osmotic pump controlled release tablet and a preparation method thereof. The preparation method of the cilnidipine osmotic pump controlled release tablet comprises the following steps: mixing cilnidipine and a cyclodextrin derivative to obtain a cilnidipine cyclodextrin inclusion compound; mixing the cilnidipine cyclodextrin inclusion compound with an osmotic pressure accelerant, a cosolvent, a disintegrating agent, an adhesive and a diluent, and granulating to obtain cilnidipine cyclodextrin inclusion compound particles; mixing and tabletting the cilnidipine cyclodextrin inclusion compound particles, a flow aid and a lubricant to obtain a cilnidipine osmotic pump controlled release tablet core; and mixing the cilnidipine osmotic pump controlled release tablet core with a pore-foaming agent, an opacifying agent, a plasticizer and a coating material, and carrying out coating treatment to obtain the cilnidipine osmotic pump controlled release tablet. The cilnidipine osmotic pump controlled release tablet prepared by the invention can prolong the action time of the medicine, improve the bioavailability of the medicine, reduce the peak-valley effect of the blood concentration of the medicine and improve the medication compliance of a patient.

1. Name of the product in this design: Tablet punching machine. 2. Application of this design: This pharmaceutical equipment is mainly suitable for the permeation of the semi-permeable membrane on the upper part of the osmotic pump tablet. It is also suitable for punching, coding, and marking solid tablets or other solid preparations in the food or pharmaceutical industry. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D rendering 1.

The invention relates to the field of pharmaceutical preparations, in particular to a sacubitril and valsartan sodium controlled-release composition, a preparation method and application thereof, and a medicine. The invention provides a double-layer osmotic pump controlled release tablet of sacubitril and valsartan sodium, the tablet can continuously release medicine within 24 hours, and the oral administration of the original developed preparation on the market is changed into the oral administration of the original developed preparation once every two days, so that the medication compliance of a patient is greatly improved. Besides, the drug release of the preparation is characterized by zero-order release, the influence of the pH value of the environment is small, the influence of the complex environment of the gastrointestinal tract in the gastrointestinal tract is small, the safety of the drug is greatly improved, the fluctuation of the blood concentration caused by the peak valley effect of a common quick-release tablet is avoided, the steady-state blood concentration can be achieved after the preparation is taken once, and the preparation is safe and reliable. The effectiveness of the medicine is improved.